Mechanistic studies showed that depletion of CD11c+ cells or lack of CD8α+ DCs attenuated the anti-tumor response generated by Flagrp170 therapy, suggesting that Flagrp170-enhanced activation of tumor-specific CTLs depends on these DCs for efficient antigen cross-presentation (173). The gene discussed is CD8A; the disease is neoplasm.